1.
Belgian retrospective survey of hereditary transthyretin-mediated (hATTR) amyloidosis patients treated with patisiran in real-world practice
2.
3.
4.
Late-onset Pompe disease (LOPD) in Belgium: clinical characteristics and outcome measures
5.
6.